Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Gilead Sciences (GILD)
NASDAQ:GILD
Holding GILD?
Track your performance easily
GILD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$62.07 - $87.87
Previous Close$83.9
Volume8.93M
Average Volume (3M)6.77M
Market Cap
$104.29B
Enterprise Value$127.72B
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$23.35B
Price to Earnings (P/E)102.5
Beta0.56
Next Earnings
Nov 07, 2024EPS Estimate
$1.56Last Dividend Ex-Date
Sep 13, 2024Dividend Yield3.62%
Share Statistics
EPS (TTM)0.82
Shares Outstanding1,244,992,081
10 Day Avg. Volume7,410,784
30 Day Avg. Volume6,774,634
Standard Deviation0.07
R-Squared0.02
Alpha0.00713
Financial Highlights & Ratios
Price to Book (P/B)5.71
Price to Sales (P/S)3.72
Price to Cash Flow (P/CF)19.50
P/FCF Ratio21.60
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.59
Enterprise Value/Gross Profit6.19
Enterprise Value/Ebitda25.38
Forecast
1Y Price Target
$82.89Price Target Upside-1.05% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering23
Gilead Sciences News
Bulls Say, Bears Say
Bulls Say
Market ExpansionLenacapavir’s differentiated product profile and strong demand for a 6-month subcutaneous PrEP option could significantly accelerate the growth and expansion of the PrEP market.
Market OpportunityThe acquisition of CBAY and potential market exit of a competitor drug give Gilead a wide open market opportunity for its new drug in PBC.
Product EfficacyLenacapavir has shown unparalleled efficacy with a 96% reduction in HIV infections, demonstrating superiority over existing options like Truvada.
Bears Say
Commercial RiskThere is significant commercial risk and uncertainty for len in HIV PrEP.
Oncology SegmentYescarta continues to be pressured by competition and drags GILD's US Oncology segment.
Sales GrowthFlat HIV sales growth for FY25 is an overhang.
---
Ownership Overview
0.91% Insiders
30.53% Mutual Funds
50.56% Other Institutional Investors
18.01% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
ProductionRisks related to the company’s ability to manufacture goods and services
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GILD FAQ
What was Gilead Sciences’s price range in the past 12 months?
Gilead Sciences lowest stock price was $62.07 and its highest was $87.86 in the past 12 months.
What is Gilead Sciences’s market cap?
Currently, no data Available
When is Gilead Sciences’s upcoming earnings report date?
Gilead Sciences’s upcoming earnings report date is Nov 07, 2024 which is in 48 days.
How were Gilead Sciences’s earnings last quarter?
Gilead Sciences released its earnings results on Aug 08, 2024. The company reported $2.01 earnings per share for the quarter, beating the consensus estimate of $1.607 by $0.403.
Is Gilead Sciences overvalued?
According to Wall Street analysts Gilead Sciences’s price is currently Overvalued.
Does Gilead Sciences pay dividends?
Gilead Sciences pays a Quarterly dividend of $0.77 which represents an annual dividend yield of 3.62%. See more information on Gilead Sciences dividends here
What is Gilead Sciences’s EPS estimate?
Gilead Sciences’s EPS estimate is $1.56.
How many shares outstanding does Gilead Sciences have?
Gilead Sciences has 1,244,992,100 shares outstanding.
What happened to Gilead Sciences’s price movement after its last earnings report?
Gilead Sciences reported an EPS of $2.01 in its last earnings report, beating expectations of $1.607. Following the earnings report the stock price went down -2.55%.
Which hedge fund is a major shareholder of Gilead Sciences?
Among the largest hedge funds holding Gilead Sciences’s share is Dodge & Cox. It holds Gilead Sciences’s shares valued at 2B.
---
Gilead Sciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$82.89 (-1.05% Downside)
$82.89 (-1.05% Downside)
Blogger Sentiment
Bullish
GILD Sentiment 94%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 984.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 2.0%
Last 30 Days ▼ 2.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
15.33%
12-Months-Change
Fundamentals
Return on Equity
5.34%
Trailing 12-Months
Asset Growth
-14.05%
Trailing 12-Months
Company Description
Gilead Sciences
Founded in 1987, California-based Gilead Sciences, Inc. is a biopharmaceutical company, which focuses on the research, development, and commercialization of antiviral drugs used in the treatment of diseases like human immunodeficiency virus (HIV), hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi. It offers its products under brands including Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi.
---
GILD Company Deck
---
GILD Earnings Call
Q2 2024
0:00 / 0:00
---
GILD Revenue Breakdown
67.03% HIV
8.05% Veklury
6.89% Cell Therapy
6.52% HCV
11.51% Other
---
GILD Stock 12 Month Forecast
Average Price Target
$82.89
▼(-1.05% Downside)
Technical Analysis
Best Analysts Covering GILD
1 Year
1 Year Success Rate
22/33 ratings generated profit
1 Year Average Return
+10.10%
reiterated a buy rating last month
Copying Hartaj Singh's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +10.10% per trade.
---